CLEVELAND BIOLABS INC Business Finance Contracts & Agreements
79 Contracts & Agreements
- Assignment Agreements (2 contracts)
- Investment Agreements (4)
- Loan Agreements (5)
- Modification Agreements (7)
- Note Agreements (4)
- Participation Agreements (3)
- Purchase Agreements (16)
- Registration Rights Agreements (6)
- Release Agreements (1)
- Share Agreements (1)
- Stock Agreements (4)
- Underwriting Agreements (2)
- Waiver Agreements (1)
- Warrant Agreements (23)
- Amended and Restated Convertible Note Due May 1, 2024, dated as of November 7, 2022 (Filed With SEC on November 15, 2022)
- Assignment of Promissory Note, dated November 7, 2022, by and among Avenue Venture Opportunities Fund, L.P., Silverback Capital Corporation and Statera Biopharma, Inc (Filed With SEC on November 15, 2022)
- Form of Securities Purchase Agreement by and between the Company and the purchasers named therein (Filed With SEC on November 7, 2022)
- Form of Common Stock Purchase Warrant (Filed With SEC on November 7, 2022)
- Warrant Agency Agreement dated March 24, 2022 (Filed With SEC on October 28, 2022)
- Amended and Restated Convertible Note Due May 1, 2024, dated as of October 18, 2022 (Filed With SEC on October 24, 2022)
- Assignment of Promissory Note, dated October 18, 2022, by and among Avenue Venture Opportunities Fund, L.P., Silverback Capital Corporation and Statera Biopharma, Inc (Filed With SEC on October 24, 2022)
- Warrant Agency Agreement, dated as of March 24, 2022, by and between the Company and Continental Stock Transfer & Trust Company, LLC (Filed With SEC on October 21, 2022)
- Forbearance and Second Amendment to Loan Documents, dated April 18, 2022 (Filed With SEC on May 27, 2022)
- Form of Form of Pre-funded Warrant (Filed With SEC on March 25, 2022)
- Form of Five Year Common Stock Purchase Warrant (Filed With SEC on March 25, 2022)
- Form of One Year Common Stock Purchase Warrant (Filed With SEC on March 25, 2022)
- Form of Underwriting Agreement, dated March 22, 2022, by and between Statera Biopharma, Inc. and EF Hutton, a division of Benchmark Investments, LLC (Filed With SEC on March 25, 2022)
- Form of Waiver (Filed With SEC on March 22, 2022)
- Form of Securities Purchase Agreement, dated February 6, 2022, by and between Statera Biopharma, Inc. and the investor party thereto (Filed With SEC on February 7, 2022)
- Form of Common Stock Purchase Warrant (Filed With SEC on February 7, 2022)
- Amended and Restated Registration Rights Agreement, dated as of July 27, 2021, by and among GEM Global Yield LLC SCS, GEM Yield Bahamas Limited and Cytocom Inc (Filed With SEC on August 2, 2021)
- Warrant to Purchase Shares of Cytocom Inc., dated as of July 27, 2021, issued to GEM Yield Bahamas Limited (Filed With SEC on August 2, 2021)
- Amended and Restated Share Purchase Agreement, dated as of July 27, 2021, by and among GEM Global Yield LLC SCS, GEM Yield Bahamas Limited and Cytocom Inc (Filed With SEC on August 2, 2021)
- Warrant to Purchase Shares of Common Stock of Cytocom Inc., dated as of July 27, 2021, issued to Avenue Venture Opportunities Fund, L.P (Filed With SEC on August 2, 2021)
- Supplement to the Loan and Security Agreement dated as of April 26, 2021 between Cytocom, Inc. and Avenue Venture Opportunities Fund, L.P (Filed With SEC on August 2, 2021)
- Loan and Security Agreement, dated as of April 26, 2021, by and among Cytocom, Inc. and Avenue Venture Opportunities Fund, L.P (Filed With SEC on August 2, 2021)
- Form of Securities Purchase Agreement, dated as of February 19, 2021, between Cleveland BioLabs, Inc. and the purchasers named therein (Filed With SEC on February 23, 2021)
- Form of Placement Agent Warrant (Filed With SEC on February 23, 2021)
- Award/Contract W81XWH-15-0570 modification dated September 29, 2020 issued by USA Med Research ACQ Activity (Filed With SEC on November 16, 2020)
- Award/Contract W81XWH-15-0101 modification dated September 29, 2020 issued by USA Med Research ACQ Activity (Filed With SEC on November 16, 2020)
- Award/Contract W81XWH-15-0570 modification dated July 31, 2020 issued by USA Med Research ACQ Activity (Filed With SEC on August 14, 2020)
- Award/Contract W81XWH-15-0101 modification dated July 31, 2020 issued by USA Med Research ACQ Activity (Filed With SEC on July 31, 2020)
- Form of Securities Purchase Agreement, dated as of June 1, 2020, between Cleveland BioLabs, Inc. and the purchasers named therein (Filed With SEC on June 3, 2020)
- Form of Placement Agent Warrant (Filed With SEC on June 3, 2020)
- Form of Warrant (Filed With SEC on June 3, 2020)
- Award/Contract W81XWH-15-0101 modification dated March 18, 2020 issued by USA Med Research ACQ Activity (Filed With SEC on April 15, 2020)
- Award/Contract W81XWH-15-C-0101 modification dated February 28, 2019 issued by USA Med Research ACQ Activity (Filed With SEC on May 15, 2019)
- Director Designation Agreement, dated as of August 10, 2018, among Genome Protection, Inc., Everon Biosciences, Inc., Cleveland BioLabs, Inc. and Norma Investments Limited (Filed With SEC on August 14, 2018)
- Simple Agreement for Future Equity, dated as of August 10, 2018, among Genome Protection, Inc., Norma Investments Limited, Cleveland BioLabs, Inc. and Everon Biosciences, Inc (Filed With SEC on August 14, 2018)
- Assignment Agreement, dated as of August 6, 2018, between Cleveland BioLabs, Inc. and Genome Protection, Inc (Filed With SEC on August 10, 2018)
- Award/Contract W81XWH-15-C-0101 modification dated September 14, 2017 issued by USA Med Research ACQ Activity (Filed With SEC on November 14, 2017)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on June 24, 2015)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 24, 2015)
- FIRST AMENDMENT TO 2013 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on April 17, 2015)
